Liontrust Investment Partners LLP discloses 4.9% stake in Maxcyte
Maxcyte
- 4.9%[1]
Liontrust Investment Partners LLP reported a 4.9% stake in Maxcyte (MXCT) in a Schedule 13D filed with the SEC on Nov 2, 2026. The filing covers 5,081,403 shares and cuts its earlier 5% stake.[1]
| Reporting person | Security | Shares | Ownership | Filed |
|---|---|---|---|---|
| Liontrust Investment Partners LLP | Maxcyte, Inc | 5,081,403 | 4.9% | 2026-11-02 |
MXCT insider trading activity
In open-market trades dated in the last 90 days, 1 insider bought $121K and no insider sold, per Form 4 filings.
- Maher Masoud (President and CEO) bought 100,000 shares for $121K, last filed Nov 18.
Get MXCT alerts
Set a MXCT price alert, or get one when a fund, insider or politician you follow trades.
Sources
Keep reading
Built by fixed rules from the filing as filed, with no AI writing. A filing does not show why anyone traded. Report a correction.